Posted by Michael Wonder on 24 Jan 2022
People with chronic myeloid leukaemia granted early access to Novartis’ investigational treatment
24 January 2022 - The Medicine and Healthcare products Regulatory Agency grants positive scientific opinion on use of asciminib as 3rd-line treatment option for adults with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase without T315I mutation under the UK Early Access to Medicines Scheme.
The decision means that adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase without T315I mutation who have previously been treated with two or more tyrosine kinase inhibitors may now potentially gain access to asciminib while the relevant regulatory bodies continue to review the Marketing Authorisation Application.
